【摘要】 目的 分析丁苯酞联合依达拉奉右莰醇治疗急性缺血性脑卒中(AIS)的效果及安全性。方法 88例AIS患者,根据治疗方法不同分为对照组与观察组,各44例。对照组采用丁苯酞治疗,观察组增加依达拉奉右莰醇治疗。比较两组临床疗效、神经功能[美国国立卫生研究院卒中量表(NIHSS)、改良Rankin量表(mRS)评分]及不良反应发生情况。结果 观察组总有效率90.91%高于对照组的75.00%(P<0.05)。治疗后,两组NIHSS、mRS评分均低于本组治疗前,且观察组NIHSS评分(9.29±1.34)分、mRS评分(2.09±0.34)分低于对照组的(10.33±1.67)、(2.43±0.67)分(P<0.05)。观察组不良反应发生率为13.64%,与对照组的15.91%比较无差异(P>0.05)。结论 丁苯酞联合依达拉奉右莰醇治疗AIS的效果显著,能够促使患者神经功能恢复,且与单独应用丁苯酞治疗的不良反应发生率无差异。更多还原

【Abstract】 Objective To analyze the efficacy and safety of combined treatment withbutylphthalide and edaravone and dexborneol in acute ischemic stroke(AIS). Methods 88 patients with AIS were selected and allocated to the control group and the observation group by different treatment methods, each comprising 44 cases. The control group was treated with butylphthalide, while the observation group was treated with butylphthalide in combination with edaravone and dexborneol. The clinical efficacy, neurological function [National Institutes of Health Stroke Scale(NIHSS) and Modified Rankin Scale(mRS) scores] and adverse reactions were compared between the two groups. Results The overall response rate of the observation group(90.91%) was higher than that of the control group(75.00%)(P<0.05). After treatment, the NIHSS and mRS scores in both groups were lower than those before treatment in this group, and the observation group had lower NIHSS score(9.29±1.34) points and mRS score(2.09±0.34) points than the control group [(10.33±1.67) and(2.43±0.67) points](P<0.05). The incidence of adverse reactions in the observation group was 13.64%, which was not different from that of the control group(15.91%)(P>0.05). Conclusion The therapeutic effect of combination of butylphthalide and edaravone and dexborneol is significant in the treatment of AIS, which can promote the recovery of neurological function, and there is no difference in the incidence of adverse reactions compared with butylphthalide alone.更多还原